English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Chemotherapy‐induced peripheral neurotoxicity ( CIPN ) seriously impairs patients’ quality of life cumulatively and dose‐dependently. Because assessment of  CIPN  usually depends on patients’ subjective evaluation of symptoms, objective and quantitative measures are needed. We evaluated a point‐of‐care nerve conduction device ( POCD ), previously validated for the assessment of diabetic peripheral neuropathy. Sensory nerve action potential ( SNAP ) amplitude and sensory nerve conduction velocity ( SNCV ) of the sural nerve were measured using a portable, automated  POCD  (DPNCheck; NeuroMetrix Inc., Waltham, MA, USA) in patients with a clinical diagnosis of  CIPN  of grade 1 or higher. We compared  SNAP  and  SNCV  among patients with different grades of  CIPN  according to the Common Terminology Criteria for Adverse Events. A total of 50 patients (22 men, 28 women; median age, 64 years; grade 1/2/3, 21/18/11) were evaluated. Anticancer drugs responsible for  CIPN  were cisplatin in five patients, oxaliplatin in 15, carboplatin in 5, paclitaxel in 16, docetaxel in 14, nab‐paclitaxel in 7, vincristine in 6, and bortezomib in 3. Unadjusted  SNAP  was 8.45 ± 3.67 μV (mean ± SD) in patients with grade 1  CIPN , 5.42 ± 2.68 μV with grade 2, and 2.45 ± 1.52 μV with grade 3. Unadjusted  SNCV  was 49.71 ± 4.77 m/s in patients with grade 1  CIPN , 48.78 ± 6.33 m/s with grade 2, and 44.14 ± 7.31 m/s with grade 3. The adjusted  SNAP  after controlling for age significantly differed between each  CTCAE  grade ( P  < 0.001,  ancova ). The adjusted  SNCV  after controlling for age and height also differed significantly ( P  = 0.027). Differences in the severity of  CIPN  could be detected objectively and quantitatively using this  POCD .

Quantitative assessment of chemotherapy‐induced peripheral neurotoxicity using a point‐of‐care nerve conduction device